Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

NCT01505777 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome Without Diarrhea

Interventions

DRUG: Probiotics (Medirac)
DRUG: Probiotics (Medirac)
DRUG: Probiotics (Medirac)
DRUG: Probiotics (Medirac)
DRUG: Probiotics (Medirac) placebo/mosapride placebo

Sponsor

Hanmi Pharmaceutical Company Limited